The nurse is caring for a group of medical-surgical patients. The unit has been notified of a fire on an adjacent wing of the hospital. The nurse quickly formulates a plan to keep the patients safe. Which actions will the nurse take?
(Select all that apply.)
a. Close all doors.
b. Note evacuation routes.
c. Note oxygen shut-offs.
d. Move bedridden patients in their bed.
e. Wait until the fire department arrives to act.
f. Use type B fire extinguishers for electrical fires.
ANS: A, B, C, D
Closing all doors helps to contain smoke and fire. Noting the evacuation routes and oxygen shut-offs is important in case evacuation is needed. You will move bedridden patients from the scene of a fire by a stretcher, bed, or wheelchair. The nurse cannot wait until the fire department arrives to act. Type C fire extinguishers are used for electrical fires; type B is used for flammable liquids.
You might also like to view...
A nurse is caring for a patient who has an immunodeficiency. What assessment finding should prompt the nurse to consider the possibility that the patient is developing an infection?
A) Uncharacteristic aggression B) Persistent diarrhea C) Pruritis (itching) D) Constipation
Hildegard Peplau's Theory of Interpersonal Relations focuses on which of the following?
a. The relationship between nurse and doctor b. The mutual caring relationship c. Meeting the needs of nurse and patient d. The relationship between nurse and patient
Why is an infusion of muromonab-CD3 (Orthoclone) more likely to result in an allergic reaction than an infusion of mycophenolate (CellCept)?
a. Muromonab-CD3 is administered for shorter time periods than is mycophenolate. b. Muromonab-CD3 is administered in much higher dosages than is mycophenolate. c. Mycophenolate is an antiproliferative agent and muromonab-CD3 is a polyclonal antibody. d. Mycophenolate is a synthetically manufactured drug and muromonab-CD3 is produced using mouse proteins.
Which of the following best describes ongoing quality improvement (QI)?
A. Identification of critical pathway va-riances B. Evaluation of patients' minimum data sets C. Measurement of patient satisfaction levels D. Ongoing evaluation of quality and patient outcomes